HVHannah K. Vanyai

Hannah K. Vanyai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hannah K. Vanyai has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel mouse model recapitulates features of the neurodevelopmental disorder 3p25.3 microdeletion syndrome

    by Sophie Tb Morgan, Andrew Kueh, Andrew Keniry, Samantha Eccles, Marnie E Blewitt, Hannah K Vanyai

    Neurodevelopmental disorders globally affect approximately 15% of children and adolescents, but many disorders do not have mouse models, thus limiting our ability to further understand them and ultimately develop treatments. In our study, we developed a novel mouse line to model 3p25.3 microdeletion syndrome ( 6qE3 del/+ ) that reliably recapitulates key features of the syndrome. 6qE3 del/+ mice display congenital heart defects, craniofacial defects, skeletal anomalies and brain changes. We also generated another neurodevelopmental disorder model for a gene often included in the deleted region, Brpf1 , and found that congenital heart defects and craniofacial defects may be partly attributable to the heterozygous loss of Brpf1 in 6qE3 del/+ mice. Together our work offers new neurodevelopment models, and provides evidence that treatments developed for Brpf1 haploinsufficiency may also benefit 3p25.3 microdeletion syndrome.

  • Open Access

    SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome

    by Megan Iminitoff, Anna Le Fevre, Tamara Cameron, Hannah K. Vanyai, Caleb Chew, Sarah A. Kinkel, Kelsey Breslin, Susanne Theiß, Quentin Gouil, Merlin Thomas, et al.

    Prader-Willi syndrome (PWS) is a neurodevelopmental disorder caused by loss of expression from the active paternal allele at an imprinted cluster on chromosome 15. Current treatments address individual symptoms rather than the underlying cause of disease. Because all patients preserve a normal but epigenetically silenced maternal copy of these genes, activation of this copy offers a potential disease-modifying therapy. Here, we investigated the epigenetic regulator SMCHD1. First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target. Second, we found that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role beyond only part of the cluster. Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus and improved phenotypes in a PWS mouse model. Despite broader genome-wide binding, postearly development targeting of SMCHD1 appeared remarkably safe, supporting its potential for gene activation therapy for PWS.

  • Open Access

    SMCHD1 is a novel target for gene-activation therapy to treat Prader-Willi Syndrome

    by Megan Iminitoff, Anna Le Fevre, Tamara Cameron, Hannah K Vanyai, Caleb Chew, Sarah A Kinkel, Kelsey Breslin, Susanne Theiss, Quentin Gouil, Merlin Thomas, et al.

    Prader-Willi Syndrome (PWS) is a neurodevelopmental disorder caused by lack of gene expression from the active paternal allele at an imprinted gene cluster on chromosome 15. Current treatments have limited efficacy as they target individual symptoms rather than the underlying cause of disease. All patients preserve a normal, yet epigenetically-silenced, copy of the PWS cluster genes; activation of this imprinted copy to restore necessary gene expression is an appealing option for tackling the root of the disorder. Here we have addressed the potential to activate these silent maternal genes by targeting the epigenetic regulator Structural Maintenance of Chromosomes Hinge domain containing 1 (SMCHD1). First, we expanded the role of SMCHD1 in repressing the PWS cluster from mice to humans, a critical step if SMCHD1 is to be a drug target. Second, we discovered that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role at only half of the PWS genes. We show that deleting Smchd1 after early development in vivo is effective at causing PWS gene-activation in disease-relevant mouse tissues including hypothalamus, and that this has beneficial effects on phenotypes observed in a PWS mouse model. Despite SMCHD1 having a role in gene silencing elsewhere in the genome, our data suggest that targeting SMCHD1 after early development is remarkably safe. Taken together, these data propose SMCHD1 as a novel target for gene-activation therapy for PWS.

  • Open Access

    DNA binding by ATPase-adjacent domains stimulates SMCHD1 ATPase activity

    by Alexandra D. Gurzau, Richard W. Birkinshaw, Andrew Leis, Tamara Cameron, Megan Iminitoff, Kelsey Breslin, Iromi Wickramasinghe, Samantha Eccles, Hannah K. Vanyai, Quentin A. Gouil, et al.

    SMCHD1 is an epigenetic regulator in which heterozygous variants are reported in facioscapulohumeral muscular dystrophy (FSHD), as well as Bosma arhinia microphthalmia syndrome (BAMS). While we have previously shown that SMCHD1 is able to interact with nucleic acids via its hinge domain, we have now identified a second DNA-binding site that is located C-terminal to the ATPase domain and formed by two domains: the Bromo-adjacent homology (BAH) and immunoglobulin-like 1 (IGL-1) domains. Here, we report their mode of DNA-interaction and we present the first high-resolution structure of the wild-type human SMCHD1 ATPase using site-directed mutagenesis and structural analysis via cryo-EM. We also reveal that DNA-binding at the BAH-IGL-1 domains stimulates the ATPase activity of full-length SMCHD1 in vitro , and demonstrate in a mouse model that ATP hydrolysis is essential for SMCHD1 function in vivo . Together, these findings establish bidentate DNA binding and DNA-stimulated ATP hydrolysis as central features of SMCHD1 function, providing new mechanistic insight into how SMCHD1 regulates gene silencing. GRAPHICAL